Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

This article was originally published here

The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive

The post Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply